|4May 8, 4:10 PM ET

Caissa Capital Management ltd. 4

4 · Avalo Therapeutics, Inc. · Filed May 8, 2023

Insider Transaction Report

Form 4
Period: 2023-05-04
Transactions
  • Purchase

    Common Stock

    2023-05-05$2.88/sh+5,000$14,3751,337,700 total(indirect: See Footnote (1))
  • Purchase

    Common Stock

    2023-05-08$2.62/sh+5,000$13,1081,342,700 total(indirect: See Footnote (1))
  • Purchase

    Common Stock

    2023-05-04$2.79/sh+15,000$41,8821,332,700 total(indirect: See Footnote (1))
Holdings
  • Common Stock

    182,300
Footnotes (5)
  • [F1]Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.58 to $2.85, inclusive.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.9, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $2.68, inclusive.
  • [F5]These shares are directly owned by Mr. Golestaneh in his personal capacity.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT